Recent reports have depicted highly profitable snack and fast food companies quaking in their boots over the threats posed by appetite-suppressing drugs like Ozempic. These pearl-clutching (or more aptly, Pringles-clutching) reports are likely premature. That’s largely because weight-loss drug usage isn’t yet widespread enough to make a difference to the food economy. As more weight-loss drugs are developed and approved by the FDA, that could all change. But the stars must align, and in this case that means: Shortages cease and there are enough injectables to go around; the price comes down to an affordable level for the average…
